Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Rocket Pharmaceuticals

Gene therapy may slow progression of a life-threatening cardiac ailment

The investigational treatment targets the loss of function of a gene implicated in many cases of ARVC, plakophilin-2 (PKP2). Read further on Dynamite News:

Dynamite News

Rocket Pharmaceuticals Stock Sees Improved Price Strength

Rocket Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher

A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Betting on Rocket Pharmaceuticals (RCKT)? Check the Options Flow Data First.

Although Rocket Pharmaceuticals lived up to its name on Wednesday due to an encouraging clinical trial development, the big dogs have some questions about RCKT stock.

Barchart

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Upgrades

Benzinga

Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade

Rocket Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Analyst Ratings for Rocket Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Rocket Pharmaceuticals (NASDAQ:RCKT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Organisations

American Airlines Group

57 stories

Stryker

54 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.